4//SEC Filing
Lichter Jay 4
Accession 0001415889-24-025436
CIK 0001817713other
Filed
Oct 17, 8:00 PM ET
Accepted
Oct 18, 6:51 PM ET
Size
70.4 KB
Accession
0001415889-24-025436
Insider Transaction Report
Form 4
Avalon BioVentures I, LP
10% Owner
Transactions
- Sale
Common Stock
2024-10-16$50.61/sh−29,474$1,491,679→ 2,731,817 total - Sale
Common Stock
2024-10-16$49.69/sh−60,179$2,990,295→ 2,761,291 total - Sale
Common Stock
2024-10-16$50.61/sh−5,710$288,983→ 529,173 total(indirect: By Avalon BioVentures I, LP) - Exercise/Conversion
Common Stock
2024-10-16$17.00/sh+4,968$84,456→ 11,855 total - Exercise/Conversion
Common Stock
2024-10-16$10.73/sh+2,070$22,211→ 13,925 total - Sale
Common Stock
2024-10-18$50.30/sh−104,892$5,276,068→ 2,684,380 total(indirect: By Avalon BioVentures SPV I, L.P.) - Exercise/Conversion
Common Stock
2024-10-17$13.22/sh+348$4,601→ 7,977 total - Sale
Common Stock
2024-10-18$50.30/sh−102,732$5,167,420→ 2,629,085 total - Sale
Common Stock
2024-10-16$49.69/sh−11,657$579,236→ 534,883 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-16$49.69/sh−61,445$3,053,202→ 2,819,366 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-16$50.61/sh−30,094$1,523,057→ 2,789,272 total(indirect: By Avalon BioVentures SPV I, LP) - Sale
Common Stock
2024-10-18$50.30/sh−19,900$1,000,970→ 509,273 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-18$51.18/sh−15,788$808,030→ 2,668,592 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-18$44.75/sh−104,957$4,696,826→ 401,321 total(indirect: By Avalon BioVentures I, LP) - Exercise/Conversion
Common Stock
2024-10-16$13.22/sh+2,070$27,365→ 15,995 total - Exercise/Conversion
Common Stock
2024-10-16$39.80/sh+1,407$55,999→ 17,402 total - Sale
Common Stock
2024-10-16$50.80/sh−10,957$556,616→ 6,445 total - Exercise/Conversion
Common Stock
2024-10-17$17.00/sh+836$14,212→ 7,281 total - Exercise/Conversion
Common Stock
2024-10-17$10.73/sh+348$3,734→ 7,629 total - Exercise/Conversion
Common Stock
2024-10-17$39.80/sh+237$9,433→ 8,214 total - Sale
Common Stock
2024-10-17$50.02/sh−1,843$92,187→ 6,371 total - Sale
Common Stock
2024-10-18$51.18/sh−15,462$791,345→ 2,613,623 total - Sale
Common Stock
2024-10-18$51.18/sh−2,995$153,284→ 506,278 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-18$44.75/sh−541,824$24,246,624→ 2,071,799 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−4,968→ 22,776 totalExercise: $17.00Exp: 2027-07-19→ Common Stock (4,968 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−2,070→ 9,490 totalExercise: $10.73Exp: 2027-07-19→ Common Stock (2,070 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−2,070→ 9,490 totalExercise: $13.22Exp: 2027-07-19→ Common Stock (2,070 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−1,407→ 6,309 totalExercise: $39.80Exp: 2027-07-19→ Common Stock (1,407 underlying) - Sale
Common Stock
2024-10-18$44.75/sh−553,219$24,756,550→ 2,115,373 total(indirect: By Avalon BioVentures SPV I, L.P.) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−836→ 21,940 totalExercise: $17.00Exp: 2027-07-19→ Common Stock (836 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−348→ 9,142 totalExercise: $10.73Exp: 2027-07-19→ Common Stock (348 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−348→ 9,142 totalExercise: $13.22Exp: 2027-07-19→ Common Stock (348 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−237→ 6,072 totalExercise: $39.80Exp: 2027-07-19→ Common Stock (237 underlying)
Lichter Jay
Director10% Owner
Transactions
- Sale
Common Stock
2024-10-16$49.69/sh−61,445$3,053,202→ 2,819,366 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-18$50.30/sh−104,892$5,276,068→ 2,684,380 total(indirect: By Avalon BioVentures SPV I, L.P.) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−2,070→ 9,490 totalExercise: $13.22Exp: 2027-07-19→ Common Stock (2,070 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−836→ 21,940 totalExercise: $17.00Exp: 2027-07-19→ Common Stock (836 underlying) - Sale
Common Stock
2024-10-18$50.30/sh−19,900$1,000,970→ 509,273 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-18$51.18/sh−15,462$791,345→ 2,613,623 total - Exercise/Conversion
Common Stock
2024-10-16$10.73/sh+2,070$22,211→ 13,925 total - Sale
Common Stock
2024-10-16$50.80/sh−10,957$556,616→ 6,445 total - Exercise/Conversion
Common Stock
2024-10-17$17.00/sh+836$14,212→ 7,281 total - Sale
Common Stock
2024-10-16$50.61/sh−29,474$1,491,679→ 2,731,817 total - Sale
Common Stock
2024-10-16$50.61/sh−5,710$288,983→ 529,173 total(indirect: By Avalon BioVentures I, LP) - Exercise/Conversion
Common Stock
2024-10-17$10.73/sh+348$3,734→ 7,629 total - Exercise/Conversion
Common Stock
2024-10-17$13.22/sh+348$4,601→ 7,977 total - Sale
Common Stock
2024-10-18$44.75/sh−541,824$24,246,624→ 2,071,799 total - Exercise/Conversion
Common Stock
2024-10-16$17.00/sh+4,968$84,456→ 11,855 total - Exercise/Conversion
Common Stock
2024-10-16$13.22/sh+2,070$27,365→ 15,995 total - Exercise/Conversion
Common Stock
2024-10-16$39.80/sh+1,407$55,999→ 17,402 total - Exercise/Conversion
Common Stock
2024-10-17$39.80/sh+237$9,433→ 8,214 total - Sale
Common Stock
2024-10-16$49.69/sh−60,179$2,990,295→ 2,761,291 total - Sale
Common Stock
2024-10-16$49.69/sh−11,657$579,236→ 534,883 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-16$50.61/sh−30,094$1,523,057→ 2,789,272 total(indirect: By Avalon BioVentures SPV I, LP) - Sale
Common Stock
2024-10-17$50.02/sh−1,843$92,187→ 6,371 total - Sale
Common Stock
2024-10-18$50.30/sh−102,732$5,167,420→ 2,629,085 total - Sale
Common Stock
2024-10-18$51.18/sh−2,995$153,284→ 506,278 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-18$51.18/sh−15,788$808,030→ 2,668,592 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-18$44.75/sh−104,957$4,696,826→ 401,321 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-18$44.75/sh−553,219$24,756,550→ 2,115,373 total(indirect: By Avalon BioVentures SPV I, L.P.) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−4,968→ 22,776 totalExercise: $17.00Exp: 2027-07-19→ Common Stock (4,968 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−2,070→ 9,490 totalExercise: $10.73Exp: 2027-07-19→ Common Stock (2,070 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−1,407→ 6,309 totalExercise: $39.80Exp: 2027-07-19→ Common Stock (1,407 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−348→ 9,142 totalExercise: $13.22Exp: 2027-07-19→ Common Stock (348 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−348→ 9,142 totalExercise: $10.73Exp: 2027-07-19→ Common Stock (348 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−237→ 6,072 totalExercise: $39.80Exp: 2027-07-19→ Common Stock (237 underlying)
Avalon Ventures XI, L.P.
10% Owner
Transactions
- Sale
Common Stock
2024-10-16$50.61/sh−29,474$1,491,679→ 2,731,817 total - Exercise/Conversion
Common Stock
2024-10-16$17.00/sh+4,968$84,456→ 11,855 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−237→ 6,072 totalExercise: $39.80Exp: 2027-07-19→ Common Stock (237 underlying) - Sale
Common Stock
2024-10-18$44.75/sh−541,824$24,246,624→ 2,071,799 total - Sale
Common Stock
2024-10-18$44.75/sh−104,957$4,696,826→ 401,321 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-16$49.69/sh−60,179$2,990,295→ 2,761,291 total - Sale
Common Stock
2024-10-16$50.61/sh−5,710$288,983→ 529,173 total(indirect: By Avalon BioVentures I, LP) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−2,070→ 9,490 totalExercise: $10.73Exp: 2027-07-19→ Common Stock (2,070 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−348→ 9,142 totalExercise: $10.73Exp: 2027-07-19→ Common Stock (348 underlying) - Exercise/Conversion
Common Stock
2024-10-16$10.73/sh+2,070$22,211→ 13,925 total - Exercise/Conversion
Common Stock
2024-10-16$39.80/sh+1,407$55,999→ 17,402 total - Sale
Common Stock
2024-10-16$50.80/sh−10,957$556,616→ 6,445 total - Exercise/Conversion
Common Stock
2024-10-17$39.80/sh+237$9,433→ 8,214 total - Sale
Common Stock
2024-10-17$50.02/sh−1,843$92,187→ 6,371 total - Sale
Common Stock
2024-10-18$50.30/sh−19,900$1,000,970→ 509,273 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-18$50.30/sh−104,892$5,276,068→ 2,684,380 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-18$51.18/sh−15,462$791,345→ 2,613,623 total - Sale
Common Stock
2024-10-18$51.18/sh−2,995$153,284→ 506,278 total(indirect: By Avalon BioVentures I, LP) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−4,968→ 22,776 totalExercise: $17.00Exp: 2027-07-19→ Common Stock (4,968 underlying) - Sale
Common Stock
2024-10-16$49.69/sh−11,657$579,236→ 534,883 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-16$50.61/sh−30,094$1,523,057→ 2,789,272 total(indirect: By Avalon BioVentures SPV I, LP) - Exercise/Conversion
Common Stock
2024-10-16$13.22/sh+2,070$27,365→ 15,995 total - Exercise/Conversion
Common Stock
2024-10-17$17.00/sh+836$14,212→ 7,281 total - Exercise/Conversion
Common Stock
2024-10-17$10.73/sh+348$3,734→ 7,629 total - Exercise/Conversion
Common Stock
2024-10-17$13.22/sh+348$4,601→ 7,977 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−1,407→ 6,309 totalExercise: $39.80Exp: 2027-07-19→ Common Stock (1,407 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−836→ 21,940 totalExercise: $17.00Exp: 2027-07-19→ Common Stock (836 underlying) - Sale
Common Stock
2024-10-16$49.69/sh−61,445$3,053,202→ 2,819,366 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-18$50.30/sh−102,732$5,167,420→ 2,629,085 total - Sale
Common Stock
2024-10-18$51.18/sh−15,788$808,030→ 2,668,592 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-18$44.75/sh−553,219$24,756,550→ 2,115,373 total(indirect: By Avalon BioVentures SPV I, L.P.) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−2,070→ 9,490 totalExercise: $13.22Exp: 2027-07-19→ Common Stock (2,070 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−348→ 9,142 totalExercise: $13.22Exp: 2027-07-19→ Common Stock (348 underlying)
Avalon BioVentures SPV I, L.P.
10% Owner
Transactions
- Sale
Common Stock
2024-10-16$49.69/sh−61,445$3,053,202→ 2,819,366 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-16$50.61/sh−30,094$1,523,057→ 2,789,272 total(indirect: By Avalon BioVentures SPV I, LP) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−348→ 9,142 totalExercise: $13.22Exp: 2027-07-19→ Common Stock (348 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−237→ 6,072 totalExercise: $39.80Exp: 2027-07-19→ Common Stock (237 underlying) - Sale
Common Stock
2024-10-16$50.80/sh−10,957$556,616→ 6,445 total - Exercise/Conversion
Common Stock
2024-10-17$17.00/sh+836$14,212→ 7,281 total - Exercise/Conversion
Common Stock
2024-10-17$10.73/sh+348$3,734→ 7,629 total - Exercise/Conversion
Common Stock
2024-10-17$13.22/sh+348$4,601→ 7,977 total - Sale
Common Stock
2024-10-18$50.30/sh−102,732$5,167,420→ 2,629,085 total - Sale
Common Stock
2024-10-16$50.61/sh−29,474$1,491,679→ 2,731,817 total - Exercise/Conversion
Common Stock
2024-10-17$39.80/sh+237$9,433→ 8,214 total - Sale
Common Stock
2024-10-17$50.02/sh−1,843$92,187→ 6,371 total - Sale
Common Stock
2024-10-18$44.75/sh−104,957$4,696,826→ 401,321 total(indirect: By Avalon BioVentures I, LP) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−4,968→ 22,776 totalExercise: $17.00Exp: 2027-07-19→ Common Stock (4,968 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−2,070→ 9,490 totalExercise: $10.73Exp: 2027-07-19→ Common Stock (2,070 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−2,070→ 9,490 totalExercise: $13.22Exp: 2027-07-19→ Common Stock (2,070 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−836→ 21,940 totalExercise: $17.00Exp: 2027-07-19→ Common Stock (836 underlying) - Sale
Common Stock
2024-10-16$49.69/sh−11,657$579,236→ 534,883 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-16$50.61/sh−5,710$288,983→ 529,173 total(indirect: By Avalon BioVentures I, LP) - Exercise/Conversion
Common Stock
2024-10-16$17.00/sh+4,968$84,456→ 11,855 total - Sale
Common Stock
2024-10-16$49.69/sh−60,179$2,990,295→ 2,761,291 total - Exercise/Conversion
Common Stock
2024-10-16$13.22/sh+2,070$27,365→ 15,995 total - Sale
Common Stock
2024-10-18$51.18/sh−2,995$153,284→ 506,278 total(indirect: By Avalon BioVentures I, LP) - Exercise/Conversion
Common Stock
2024-10-16$10.73/sh+2,070$22,211→ 13,925 total - Exercise/Conversion
Common Stock
2024-10-16$39.80/sh+1,407$55,999→ 17,402 total - Sale
Common Stock
2024-10-18$50.30/sh−19,900$1,000,970→ 509,273 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-10-18$50.30/sh−104,892$5,276,068→ 2,684,380 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-18$51.18/sh−15,462$791,345→ 2,613,623 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-17−348→ 9,142 totalExercise: $10.73Exp: 2027-07-19→ Common Stock (348 underlying) - Sale
Common Stock
2024-10-18$51.18/sh−15,788$808,030→ 2,668,592 total(indirect: By Avalon BioVentures SPV I, L.P.) - Sale
Common Stock
2024-10-18$44.75/sh−541,824$24,246,624→ 2,071,799 total - Sale
Common Stock
2024-10-18$44.75/sh−553,219$24,756,550→ 2,115,373 total(indirect: By Avalon BioVentures SPV I, L.P.) - Exercise/Conversion
Stock Option (right to buy)
2024-10-16−1,407→ 6,309 totalExercise: $39.80Exp: 2027-07-19→ Common Stock (1,407 underlying)
Footnotes (12)
- [F1]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $49.50 to $50.45 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.97 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F11]Shares sold in a private transaction pursuant to a stock purchase agreement dated September 12, 2024. The closing of the transaction was subject to certain customary conditions to closing, including the expiration or earlier termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The closing conditions were satisfied, and the transaction closed, on October 18, 2024.
- [F12]Immediately exercisable.
- [F2]The securities are directly held by Avalon Ventures XI, L.P. ("Avalon Ventures"). Avalon Ventures XI GP, LLC ("Avalon XI GP") is the general partner of Avalon Ventures and may be deemed to beneficially own the securities held by Avalon Ventures. Mr. Lichter is a managing member of Avalon XI GP and shares voting and investment power with respect to the securities held by Avalon Ventures. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- [F3]The securities are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is the general partner of ABV I and may be deemed to beneficially own the securities held by ABV I. Mr. Lichter is a managing member of ABV GP and shares voting and investment power with respect to the securities held by ABV I. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- [F4]The securities are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is the general partner of ABV SPV and may be deemed to beneficially own the securities held by ABV SPV. Mr. Lichter is a managing member of ABV SPV GP and shares voting and investment power with respect to the securities held by ABV SPV. Each of the Reporting Persons disclaims beneficial ownership of these securities except to the extent of his or its respective pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.
- [F5]The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $50.46 to $51.25 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F6]The securities are directly held by Mr. Lichter.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.76 to $51.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.97 to $50.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0001376355
Filing Metadata
- Form type
- 4
- Filed
- Oct 17, 8:00 PM ET
- Accepted
- Oct 18, 6:51 PM ET
- Size
- 70.4 KB